I am pleased to share encouraging news regarding our retogatein (GAD-alum) drug candidate. A peer-reviewed publication in Diabetologia reported that retogatein may delay progression from early, non-insulin-requiring Type 1 Diabetes (Stage 1 and 2 T1D) to insulin-requiring Stage 3 disease by more than five years in a genetically defined subgroup.